Beijing Danatlas Pharmaceutical Technology Co. Ltd. has discovered new peroxisome proliferator-activated receptor γ (PPARγ) modulators potentially useful for the treatment of bladder cancer.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Tianjin Hengrui Medicine Co. Ltd. have disclosed new fibroblast activation protein-α (FAPα) inhibitors covalently linked to radiolabeled chelating agents through a linker potentially useful for the treatment of cancer, inflammatory, cardiovascular disorders and more.
Prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) are highly expressed in prostate tumors and exhibit greater prostate specificity than other prostate cancer antigens, reducing the risk of off-target immune responses. Researchers from Theravectys SA and Institut Pasteur reported preclinical efficacy data for Lenti-PROST-02, a novel lentiviral immunotherapy encoding immunogenic regions of PAP and PSA for the treatment of prostate cancer.
